(Q44931488)

7 December 2017

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro (English)

1 reference

7 December 2017

1 reference

Cwynarski K

1

1 reference

7 December 2017

Laylor R

2

1 reference

7 December 2017

Macchiarulo E

3

1 reference

7 December 2017

Goldman J

4

1 reference

7 December 2017

Lombardi G

5

1 reference

7 December 2017

Melo JV

6

1 reference

7 December 2017

Dazzi F

7

1 reference

7 December 2017

1 August 2004

1 reference

7 December 2017

1 reference

7 December 2017

18

1 reference

7 December 2017

1332-1339

1 reference

7 December 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403401

7 December 2017

0 references

cites work

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Optimal analysis of composite cytokine responses during alloreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Interleukin-10 and the interleukin-10 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

7 January 2021

Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

7 January 2021

Immunosuppressive effects of defibrotide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

7 January 2021

Type I and type II T cell profiles in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

7 January 2021

Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

7 January 2021

Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403401

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403401

1 reference

Dimensions Publication ID

7 December 2017

0 references

1 reference